DSGN
Design Therapeutics Inc
NASDAQ · Biotechnology
$10.27
+0.32 (+3.22%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 133.74M | 128.39M | 127.15M |
| Net Income | -5,858,142 | -5,637,576 | -5,243,986 |
| EPS | — | — | — |
| Profit Margin | -4.4% | -4.4% | -4.1% |
| Rev Growth | +7.4% | +3.0% | +5.7% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 230.85M | 252.72M | 229.14M |
| Total Equity | 255.05M | 243.86M | 238.48M |
| D/E Ratio | 0.91 | 1.04 | 0.96 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -5,607,781 | -6,075,682 | -5,861,844 |
| Free Cash Flow | -4,251,021 | -4,814,286 | -3,496,781 |